Neurontin and its new, more potent version, Lyrica, an analgesic for the treatment of pain of fibromyalgia, are widely used for the treatment of unmarked indications that represent a clear risk to the public. The use of these great drugs was approved even though the FDA had no idea what it was really doing in the brain. A new shocking study shows that they block the formation of new brain synapses, which drastically reduces the regeneration potential of brain plasticity, which means that these drugs will cause a decrease in the brain faster than any other substance known to mankind.
The problem of these drugs is compounded by their blatant illegal marketing. Neurontin was approved by the FDA in 1994 for the treatment of epilepsy. The pain medication for fibromyalgia was the subject of an illegal off-label mass promotion that cost Warner-Lambert $ 430 million (the first off-label promotion fine). The pain medication for fibromyalgia now belongs to Pfizer. Pfizer also owns Lyrica, an extremely powerful version of Neurontin. It has been approved by the FDA for various types of pain and fibromyalgia
Lyrica for the relief of fibromyalgia is one of four drugs marketed illegally by a subsidiary of Pfizer, which resulted in a $ 2.3 billion deal against Pfizer. Although the marketing of these drugs has been heavily sanctioned, they continue to generate billions of dollars in non-conforming sales. Doctors use them for all kinds of nervous problems because they are effective in suppressing symptoms. However, such uses can no longer be justified because the actual mechanism of the drugs is finally understood and, in the long run, produces a significant reduction in the health of the nerves. The researchers in the previous study are trying to minimize the severity of drugs by saying that “adult neurons do not form many new synapses.” It just is not true.
The new science shows that brain health during aging is based on the formation of new synapses. Even these researchers have been able to question the common use of these drugs in pregnant women. How is a fetus supposed to produce new nerve cells when the mother takes a blocking medication? These are the types of situations in which the FDA should be everywhere. As usual, the FDA is considering a suicide warning for Lyrica, an analgesic for the treatment of fibromyalgia, while its unlabeled uses include bipolar disorder and migraine headaches. The FDA is likely to tighten its thumbs for the next decade on the problem of brain damage. Consumer attention.